View Older Stories View More Recent Stories

Aug 8, 2022 06:45AM Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience
Aug 4, 2022 09:52AM Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results
Jul 21, 2022 10:00AM Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement
Jun 29, 2022 06:46AM Eli Lilly & Co. (LLY) to Supply Additional 150K Doses of bebtelovimab to US Govt
Jun 29, 2022 06:45AM Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options
Jun 13, 2022 09:50PM FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata
Jun 7, 2022 05:27AM Eli Lilly & Co. (LLY) Reports New Analyses of Mounjaro Injection for Treatment of Type 2 Diabetes
Jun 7, 2022 05:26AM Eli Lilly & Co. (LLY) Reports 8 of 10 Patients Maintained Skin Clearance at One Year in Lebrikizumab Atopic Dermatitis Monotherapy Trials
Jun 7, 2022 12:01AM Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Jun 6, 2022 07:00PM New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®
Jun 6, 2022 05:47AM Eli Lilly & Co. (LLY) Reports Jardiance Decreased Relative Risk of Hospitalization for Heart Failure by 50% vs DPP-4 Inhibitors and By 30% vs GLP-1
Jun 5, 2022 04:30PM Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world evidence
Jun 4, 2022 01:42PM Eli Lilly & Co. (LLY) Reports Publication of SURMOUNT-1 Results Showing tirzepatide Achieved Between 16.0% and 22.5% Weight Loss in Adults with Obesity or Overweight
Jun 4, 2022 01:41PM Eli Lilly & Co. (LLY) Reports AWARD-PEDS Trial of Trulicity in Type 2 Diabetes Patients Showed Superior Reduction in A1C vs Placebo
Jun 4, 2022 11:00AM Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo
Jun 4, 2022 10:02AM Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight
Jun 3, 2022 10:00AM Lilly to Participate in Goldman Sachs Global Healthcare Conference
May 26, 2022 05:00PM Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 08:00AM Bigfoot Biomedical® Strengthens Leadership Team with Experienced Chief Commercial Officer
May 24, 2022 05:49AM Eli Lilly & Co. (LLY) Reports 50% of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Phase 3 Study
May 24, 2022 03:01AM Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
May 23, 2022 05:00PM Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA
May 20, 2022 08:13AM CHMP Recommends Approval of Lilly (LLY) and Incyte's (INCY) OLUMIANT (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata
May 20, 2022 08:11AM CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)
May 16, 2022 02:00PM Lilly to Participate in UBS Global Healthcare Conference 2022
May 16, 2022 05:26AM Eli Lilly & Co. (LLY) Announces Approval of Mounjaro Injection
May 13, 2022 05:54PM FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes
May 11, 2022 06:45AM Eli Lilly & Co. (LLY) and Incyte (INCY) Announce FDA Approval of OLUMIANT for Treatment of Certain Hospitalized Patients with COVID-19
May 11, 2022 06:45AM FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
May 3, 2022 02:00PM Lilly to Participate in Bank of America Securities 2022 Healthcare Conference
Apr 28, 2022 06:16AM Lilly's (LLY) tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
Apr 28, 2022 06:15AM Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1
Apr 20, 2022 09:00AM Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care
Apr 19, 2022 10:00AM Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement
Apr 11, 2022 10:16AM Eli Lilly (LLY) Reports Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
Apr 11, 2022 10:15AM Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
Apr 1, 2022 06:46AM Eli Lilly (LLY) Presents Updated Data on Retevmo in Advanced RET Fusion-Positive NSCLC at the 2022 European Lung Cancer Congress
Apr 1, 2022 06:45AM Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress
Mar 16, 2022 08:03AM Lilly (LLY) announces Jardiance phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with CKD
Mar 16, 2022 08:00AM Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
Mar 1, 2022 10:06AM Lilly (LLY) announces Jardiance provided significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial
Mar 1, 2022 10:06AM Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial
Feb 24, 2022 04:17PM Eli Lilly & Co. (LLY) Announces FDA Approval of Jardiance to Treat Adults With Heart Failure Regardless of Left Ventricular Ejection Fraction
Feb 24, 2022 04:15PM US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
Feb 2, 2022 10:00AM UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents
Nov 11, 2021 01:30PM US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction
Nov 11, 2021 08:30AM Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care
Nov 5, 2021 03:02PM Lilly's (LLY) Jardiance shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of CKD status
Nov 5, 2021 03:00PM Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status
Oct 19, 2021 06:48AM Lilly (LLY) reports Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular r
View More Recent Stories View Older Stories